U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT04822792) titled 'Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT' on March 29.
Brief Summary: PRESCIENT is a multi-center, prospective observational study aimed to detect cancers early by combined assays for serum protein markers and cell-free DNA (cfDNA) methylation markers. Blood RNA markers will also be evaluated. The study will enroll approximately 11879 participants, including participants with malignancies or benign diseases, and healthy participants.
Study Type: Observational
Condition: Cancer
Intervention: Device: Multi-cancer early detection test
Blood collection and multi-cancer early detection test
Recruitment St...